MedTrace Logo

Lansoprazole Versus Mosapride for Functional Dyspepsia

NCT00663897 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 329

Last updated 2009-10-09

No results posted yet for this study

Summary

Functional dyspepsia is a common symptom complex with significant impact on quality of life. There is no standard treatment for functional dyspepsia but therapeutic efficacy of proton pump inhibitor (PPI) and prokinetic agent have been proved in subsets of patients. This study has two aims:

* first is to compare the therapeutic efficacy of lansoprazole (a PPI) and mosapride (a prokinetic agent) for functional dyspepsia
* second is to investigate whether different subgroups of functional dyspepsia (e.g., epigastric pain syndrome and postprandial distress syndrome) respond differently to PPI and prokinetic agent.

Conditions

  • Functional Dyspepsia
  • Epigastric Pain Syndrome
  • Post Prandial Distress Syndrome

Interventions

DRUG

lansoprazole

lansoprazole, 30 mg, once daily for 14 days

DRUG

mosapride

mosapride, 5 mg, thrice daily for 14 days

Sponsors & Collaborators

  • Tomorrow Medical Foundation

    collaborator OTHER

  • Lotung Poh-Ai Hospital

    lead OTHER

Principal Investigators

  • Yao-Chun Hsu, M.D. · Lotung Poh-Ai hospital, I-Lan County, Taiwan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2009-07-31
Completion
2009-09-30

Countries

  • Taiwan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663897 on ClinicalTrials.gov